T
his is the first of three articles dealing with the International Diabetes Federation meeting, which was held in Paris, 24 -29 August 2003 . Michael Stumvoll (Tü bigen, Germany) gave the Minkowski lecture, discussing aspects of the control of glycemia, illustrating the "hyperbolic law of glucose control," depicting the inverse relationship between insulin secretion and insulin sensitivity. If one adds the 2-h glucose in a threedimensional plot, however, as insulin resistance worsens there is a progressive increase in the 2-h glucose, so that one cannot consider insulin secretion to perfectly balance the degree of insulin resistance (1). Stumvoll gave an overview of the fascinating science involved in understanding glycemia, describing the products of six genes involved in glucose homeostasis. Adiponectin is a protein released by fat cells to an extent inversely related to total body fat mass. Treatment of insulin-resistant diabetic mice with adiponectin decreases glucose levels, and in humans there is an inverse relationship between the degree of insulin resistance and the adiponectin level. Stearoyl-CoA desaturase regulates tissue lipid synthesis and is involved in the metabolism of stearate to oleate. In liver, inhibition of this enzyme prevents hepatic steatosis in leptin-deficient animals, and the oleate-tostearate ratio on liver biopsy is inversely related to the insulin sensitivity. The insulin receptor (IR) substrate (IRS)1 modulates insulin secretion, with ␤-cell overexpression of normal IRS1 increasing insulin secretion, whereas overexpression of an abnormal IRS1 decreases insulin secretion by these cells. In humans, those with the Gly972Arg IRS1 polymorphism have shown a decrease in both the firstand second-phase insulin secretory response to intravenous glucose (2) . CEACAM1 (CEA-related cell adhesion molecule 1) regulates a pathway responsible for IR internalization, and abnormality causes diabetes. CEACAM1 causes receptor-mediated hepatic insulin endocytosis and degradation in a phosphorylation-dependent manner (3) . The liver clears approximately half of the insulin molecules with each circulatory passage, a phenomenon negatively associated with free fatty acid (FFA) levels. Peroxisome proliferator-activated receptor (PPAR)␥2 is involved in transcriptional regulation of a host of processes. The Pro12Ala polymorphism affects insulin clearance, which is greatest with Ala/Ala homozygotes, which show the greatest insulininduced suppression of lipolysis, further suggesting that release of fatty acids from adipose tissue modulates hepatic insulin degradation. The final gene product Stumvoll discussed is the IR, which has fascinating effects in the central nervous system. Mice that selectively do not express the IR in the central nervous system have evidence of overall insulin resistance. Using magnetoencephalography, it is possible to detect insulin effects in the human cerebral cortex during a hyperinsulinemic clamp, with specific analysis of the auditory cortex showing insulin action on the response to sound and attenuation of this response in persons with obesity.
Type 2 diabetes treatment
At a symposium sponsored by the U.K. Prospective Diabetes Study (UKPDS), Bernard Zinman (Toronto, Canada) discussed the baseline findings of the ADOPT (A Diabetes Outcome Prospective Trial) study of 4,356 persons randomized from type 2 diabetes diagnosis to glyburide, rosiglitazone, and metformin treatment. The mean glucose at onset was ϳ150 mg/dl, ϳ80% had metabolic syndrome, which was either diagnosed based on the Adult Treatment Panel III or World Health Organization criteria, and patients from North America were somewhat younger and more obese. Of the subjects, 4.2% were GAD positive and similar in most measures to those who were negative, although with somewhat higher triglyceride and lower HDL, lower fasting insulin, and higher initial glucose, suggesting a greater degree of ␤-cell dysfunction, although similar when corrected for the degree of insulin sensitivity. Microalbuminuria was high in prevalence and associated with obesity and higher glucose and blood pressure levels. A number of presentations at the meeting addressed additional baseline findings. 2 ). The microalbuminuric persons had higher fasting glucose, HbA 1c , and blood pressure, and the urine microalbumin correlated with homeostasis model assessment of insulin resistance, Creactive protein, fibrinogen, and white blood cell count.
Rury Holman (Oxford, U.K.) presented new results from the UKPDS (see www.dtu.ox.ac.uk for UKPDS publications and Risk Engine) after 5 years poststudy monitoring that was aimed at determining whether glycemic and blood pressure levels remained stable, whether risk reductions were maintained, and whether impact was maintained on macrovascular disease of glucose control, of metformin, and of metformin plus the sulfonylureas glyburide and chlorpropamide. A total of 5,102 persons with newonset diabetes was recruited by 1991 at 23 clinical centers. The study end was in 1997, and all participating patients were informed of the results in 1998. Five-year monitoring was performed through 2002, and 10-year monitoring is in progress. The primary analysis compared diet as primary with sulfonylurea or insulin (with additional treatment only for fasting glucose Ͼ270 mg/dl) in 1,138, 1,573, and 1,156 persons, respectively. HbA 1c levels were 8.9 vs. 8.0% at study end, with levels similar in the two groups from 3 years on, and HbA 1c levels were 8.0% after 5 years. At 5 years, 58% were on insulin either alone or in addition to oral agents. The intervention decreased for total diabetes-related end points (12% at study end and 10% at 5-year follow-up; decrease remained significant). Diabetesrelated death showed a trend to benefit at study end, and at 5-year follow-up, decreased significantly by 16%. Myocardial infarction decreased 16% (P ϭ 0.052) at study end, and at 5-year follow-up, the decrease was 15% (statistically significant at P ϭ 0.042). Microvascular disease decreased 25% at study end and 28% at 5-year follow-up. Thus, diabetes-related end points, myocardial infarction, and microvascular disease were significantly benefited by glycemic treatment. Holman raised the question of whether these results suggest a "legacy effect" of having received glucose-lowering therapies, even when glycemic levels had become similar. Metformin was used in obese persons, and diabetes-related death decreased significantly by 42% at study end and, perhaps because metformin treatment was added for those who had been in the control group, by 18% at 5 years. The reductions in risk were 39 and 18% at study end and 5-year follow-up, respectively, for myocardial infarction, and there was also a significant decrease at both time points for all-cause mortality. A peculiarity of the UKPDS was the apparent adverse effect of sulfonylurea plus metformin versus sulfonylurea alone in 537 normalweight or overweight persons. The initial analysis at 6.6 years showed no significant difference in total diabetes-related end point but significant 60 and 96% increases in total and diabetes-related deaths. At 5-year follow-up, Holman reported, the increases in mortality were 29 and 37%, respectively, and were no longer statistically significant.
Steve Haffner (San Antonio, TX) discussed new strategies for prevention of type 2 diabetes and its complications, outlining the approach taken in the NAV-IGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) study. A cardiovascular disease (CVD) intervention that has been shown to have glycemic benefit, valsartan, and a glycemic intervention with nateglinide are being applied in a 2 ϫ 2 factorial study design for persons with impaired glucose tolerance (IGT). Haffner noted that IGT is common in a variety of populations that have both insulin deficiency and insulin resistance as risk factors. The use of a short-acting insulin secretagogue may limit postprandial glucose excursions, he stated, and thereby improve insulin resistance. Persons with IGT show a much steeper decline in acute insulin response than insulin sensitivity when developing diabetes, further suggesting benefit. Furthermore, the DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) study showed increased 2-h glucose to be associated with adverse outcome (4). In the Japanese Funagata cohort, the 2-h, but not fasting, glucose level was similarly an important risk factor (5) . The Captopril Prevention Project (6), HOPE (Heart Outcomes Prevention Evaluation) study (7) , SOLVD (Studies Of Left Ventricular Dysfunction) trial (8) , and ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) (9) show evidence that ACE inhibitors protect against diabetes, and the LIFE (Losartan Intervention For Endpoint Reduction in Hypertension) study (10) shows similar protection with angiotensin receptor blocker treatment. In the NAVIGATOR study, the primary end point will be the development of diabetes and overall CVD. The secondary end points will include mortality and specific CVD events, and patients with CVD and CVD risk factors will be recruited to increase the power of the study to detect latter end points.
Hertzel Gerstein (Hamilton, Canada) discussed the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) study of 5,269 persons, 86% with IGT and 43% with impaired fasting glucose (IFG), in which ramipril and rosiglitazone are being given, and in a similar 2 ϫ 2 factorial design. He pointed out that the study is predicated on the belief that prevention of diabetes will "treat the pre-diabetes conditions" and lead to a decrease in end points "because in the end diabetes is just a surrogate marker for diseases down the line." The results of a number of trials have confirmed that it is possible to prevent diabetes with a variety of glucoseoriented interventions. The STOP-NIDDM also showed 49% decreased CVD end points with acarbose treatment (11) . ACE inhibitors decrease vasoconstriction, increase pancreatic blood flow, decrease potassium loss, decrease catecholamines, decrease lipolysis and FFA levels, decrease hepatic glucose output, and increase bradykinin; have potential direct vasodilatory effects on skeletal blood flow; increase insulin-mediated vasodilation and glucose uptake; and have possible inflammatory effects. A number of studies suggest that thiazolidinediones (TZDs) decrease insulin resistance and may also improve ␤-cell function, with supporting clinical data in the TRIPOD study (12) and recent subanalysis of 585 persons with IGT randomized to troglitazone in the U.S. Diabetes Prevention Program showing a 75% decrease in diabetes vs. 58 and 31% reported with lifestyle and metformin, respectively. A carotid ultrasound substudy will involve ϳ1,000 persons, and the Epi-DREAM study will follow ϳ25,000 persons who had glucose tolerance testing in the screening studies for DREAM.
Insulin sensitizer treatment
Jim McCormack (Oxford, U.K.) discussed new approaches to the treatment of insulin resistance at a symposium on new treatments, noting that this would not simply lead to diabetes treatment, but would have many CVD benefits. Causes of insulin resistance include central adiposity, elevations in FFA and resistin levels (13), lowering of adiponectin, and lowering of hyperinsulinemia itself, the latter consideration leading to the develPerspectives on the News opment of agents that decrease insulin secretion by opening the ATP-sensitive potassium (K ATP ) channel. PPAR␥ is a specific molecular target; it's activation leads to a host of effects, including increased adipose tissue mass with change in distribution, increased HDL and LDL particles, decreased small dense LDL levels, and decreased triglyceride, FFA, and prothrombotic factors. A number of dual PPAR␣ and -␥ agents have been or are in development, including rivoglitazone (Sankyo), farglitazar (GlaxoSmithKline), ragaglitazar (Novo Nordisk), KRP-297 (Kyorin/Merck), tesaglitazar (AstraZeneca), and BMS-298585 (Bristol-Myers Squibb). Side effects such as edema and weight gain, however, have led many of these agents to be withdrawn before or during clinical trials.
Other signaling pathways of insulin action are being explored. Insulinmimetic agents and drugs stimulating IR phosphorylation may be further targets. L-783281 is such an agent. It is a small fungal metabolite that shows strong selectivity for the IR rather than receptors of other growth factors, and there is evidence for stimulation of glucose uptake (14) . As this agent works at an early step, in principle it could, however, lead to greater decrease in insulin sensitivity. Potential therapeutic targets include enzymes involved in the mitogenic pathway of insulin action, such as the inositol polyphosphate 5-phosphatase SHIP2 (15) and the mitogen-activated protein kinase pathway intermediary protein tyrosine phosphatase-1␤. Animals that do not express this gene show increased insulin sensitivity with resistance to obesity and hypertriglyceridemia in type 2 diabetic models (16) , although selective inhibitors have not been developed. McCormack noted that part of the insulin-mimetic effect of vanadate may involve this pathway, and he suggested that this is "a very attractive target." Glycogen synthase kinase-3 inhibition, which can be produced with lithium, has been thought of as another target. This is an important negative regulator of insulinstimulated glycogen metabolism, with levels increased in type 2 diabetes, perhaps playing a role in serine phosphorylation of IRS1 and hence in causing insulin resistance.
Another potential target is 11␤-hydroxysteroid dehydrogenase (11␤-HSD) 1, which converts cortisone to cortisol, with increased levels of production in visceral fat cells. Overexpression of 11␤-HSD produces a phenotype resembling the metabolic syndrome (17), while animals not expressing the gene show a lowering of glucose levels and decreased phosphoenolpyruvate carboxykinase (18) . PPAR␥ agonists decrease 11␤-HSD, and a selective inhibitor has been described as showing antidiabetic action (19) , although mutations decreasing 11␤-HSD activity in humans have been found to be associated with adrenocorticotropinmediated androgen excess and a phenotype resembling polycystic ovary syndrome (20 in the nondiabetic and diabetic subjects, respectively, with ethanol, suggesting this to mediate the improvement of insulin sensitivity and to be relevant to its cardioprotective effect.
In a study addressing the relationship between in utero growth retardation, obesity, and insulin resistance, N.S. Levitt et al. (abstract 1722) measured insulin sensitivity in 72 persons at age 25 years, with birth weight either below the 10th percentile or between the 25th and 75th percentiles. Those with BMI below the median at age 25 and normal birth weight had an insulin sensitivity (glucose uptake during a hyperinsulinemic-euglycemic clamp) of 6.02, while those below median BMI at age 25 with low birth weight had an insulin sensitivity of 6.78. Those whose BMI was above the median at age 25 had insulin sensitivities of 4.54 and 3.91, respectively, however, suggesting that the insulin resistance of low birth weight is dependent, to a large extent, on attained body mass.
A number of studies presented at the meeting compared metformin with TZDs. R 1,550 mg) , or the sulfonylurea gliclazide (up to 320 mg) daily. In a study of 597 persons receiving pioglitazone vs. 597 with metformin, 65 vs. 23% gained weight (mean weight change ϩ1.9 vs. Ϫ2.5 kg). In a comparison of 646 persons treated with pioglitazone vs. 626 with gliclazide, 72 vs. 67% gained weight (mean weight gain 2.8 vs. 1.9 kg). In combination therapy, 319 persons receiving gliclazide plus pioglitazone were compared with 320 receiving gliclazide plus metformin (weight change ϩ2.8 vs. Ϫ1 kg), with 69 vs. 31% gaining weight, and 317 persons receiving metformin plus pioglitazone were compared with 320 receiving metformin plus gliclazide (weight gain 1.5 vs. 1.3 kg), with 60 vs. 61% gaining weight. The authors concluded that with particular attention to weight control, it is possible to lessen the potential weightincreasing effect seen with both sulfonylureas and TZDs.
X. Li et al. (abstract 171) studied 12 GAD antibody-positive patients with fasting C-peptide Ն300 pmol ⅐ l Ϫ1 ⅐ l Ϫ1 , fulfilling criteria for latent autoimmune diabetes in adults treated with insulin alone or insulin plus rosiglitazone. After 1 year, HbA 1c was similar in both groups. Fasting and postprandial C-peptide decreased with insulin alone from 620 to 360 and from 1,401 to 782 pmol ⅐ l Ϫ1 ⅐ l
Ϫ1
, respectively, with an increase in daily insulin dose from 19 to 25 units, while C-peptide was stable with insulin plus rosiglitazone, with the daily insulin dose decreasing from 17 to 13 units/day. F. Ovalle and D.S.H. Bell (abstract 2267) randomized 17 persons treated with glimepiride plus metformin with HbA 1c Ͼ8% to rosiglitazone 8 mg daily or insulin for 6 months, reporting improvement in the acute insulin response to glucose in a frequently sampled intravenous glucose tolerance test with rosiglitazone but not with insulin, similarly suggesting recovery of pancreatic ␤-cell function.
Glucagon-like peptide-1 Jens Holst (Copenhagen, Denmark) discussed glucagon-like peptide (GLP)-1 analogs, pointing out that the proglucagon gene produces GLP-1 in the gut. GLP-1 potentiates glucose-induced insulin secretion; therefore, in principle, it does not produce hypoglycemia. It increases insulin biosynthesis, upregulates insulin gene expression and expression of other ␤-cell genes producing insulin, stimulates ␤-cell proliferation and differentiation of progenitor cells in the ductular epithelium, and inhibits ␤-cell apoptosis-trophic effects that are similar to those of other endocrine stimulatory hormones. GLP-1 also inhibits glucagon secretion and decreases gastrointestinal secretion and mortality, as well as inhibits appetite and food intake, and so might be termed "the diabetologist's dream," as it deceases glucose with little risk of hypoglycemia, decreases appetite and body weight, lowers FFA levels, improves insulin sensitivity, and increases ␤-cell secretion.
Initial studies of GLP-1 were reported in 1993 (21) , with evidence of benefit in persons with poorly controlled diabetes in subsequent reports (22) . Continuous subcutaneous administration of GLP-1 to persons with type 2 diabetes for 6 weeks demonstrates the potential therapeutic effect of the agent, showing 4.3 and 5.5 mmol ⅐ l Ϫ1 ⅐ l Ϫ1 decreases in fasting and mean glucose and a 1.3% decrease in HbA 1c , with weight loss occurring gradually without nausea and evidence of improvement in ␤-cell function based on C-peptide levels (23) . Native GLP-1 is rapidly degraded with a very shortcirculating half-life by dipeptidyl peptidase (DPP)-IV (24) and has extensive renal extraction, one-quarter from glomerular filtration and the remainder from tubular secretion, with similar elimination rates of GLP-1 in persons with and without type 2 diabetes (25) . Strategies being pursued include development of resistant analogs and the inhibition of GLP-1 degradation. Use of analogs or GLP-1 receptor activators resistant to DPP-IV may be promising therapeutic approaches, although it will be important to reduce the rapid 50 -70% renal elimination rate. Fast absorption from the injection site can be addressed with delayed absorption approaches.
The natural GLP-1 receptor agonist exendin-4, found in the saliva of the Gila monster (Heloderma suspectum), has possible endocrine function related to metabolic control in this lizard. Interestingly, the animal has its own GLP-1 with high homology to human GLP-1. Exendin-4 is a full agonist to the GLP-1 receptor and is cleared mainly by glomerular filtration but not by tubular uptake, with a biological effect for ϳ12 h following administration. In a 4-week study, AC2993 (Synthetic Exendin-4) led to a significant decrease in postprandial glucose and a 1.1% decrease in HbA 1c (26) . Nausea, which is seen early in treatment and is relatively mild, occurred in 31% and hypoglycemia in 15% of patients, although only with sulfonylurea administration. Amylin Pharmaceuticals has reported a 6-month phase 3 study with 336 patients inadequately responding to metformin, with doses of 5-10 g twice daily, and the higher dose was associated with a decrease in HbA 1c from 8.2 to 7.3% (27) . Several albumin-based GLP-1 analogs are being developed. A Novo Nordisk agent, liraglutide (NN2211), has a 12-h half-life. After a single dose at bedtime in persons with type 2 diabetes, the glucoselowering effect can be demonstrated the next morning (28) . Like GLP-1, the agent improves ␤-cell sensitivity to glucose in humans, and increases ␤-cell mass in animal models, with evidence of decreased cytokine-induced ␤-cell apoptosis. In a 12-week phase 2 study, an effect similar to glimepiride has been reported in reducing HbA 1c , with decreased body weight in comparison to the sulfonylurea treatment and hypoglycemia in 0.7% vs 15%, with nausea seen during the first few weeks of treatment. Holst commented that tacchyphylaxis appears to occur to nausea but not to glycemic effects. Neurologic side effects are seen in rodent models, and increased blood pressure is seen at high doses, but this does not occur in human studies, and antibody production has not been seen at this point. Albugon from Human Genome Sciences has a 3-day half-life, with human studies pending, and a GLP-1-albumin conjugate with a 10-to 12-day half-life in humans, CJC-1131, has been reported by Conjuchem. "What we do with GLP-1," Holst concluded, "is to substitute something that is missing in the diabetic pa- In a related presentation, Sergei Zaitsev (Moscow, Russia) discussed imidazolines as novel insulinotropic compounds. Glucose induces insulin secretion via metabolism in order to increase ATP, closing the K ATP channel, leading to increases in the intracellular calcium concentration. ATP, and perhaps other glucose metabolites, also has direct effect on insulin exocytosis. Zaitsev's group has studied organic compounds possessing activity similar to GLP-1, which can be administered orally. Phentolamine, an ␣-adrenergic blocker with an imidazoline ring, stimulates insulin secretion. Another insulinotropic imidazoline, RX871024, a close analog without adrenergic blocking effect, increases islet insulin secretion. In vitro, it inhibits the K ATP channel, and in vitro, it increases islet insulin secretion in a glucose-dependent manner. It also has a direct (K ATP channel-independent) effect in increasing insulin secretion at high-but not low-glucose levels, but only in diazoxide-treated depolarized cells and in "permeabliized" islet cells with membrane defects. The K ATP -independent effect depends on protein kinases A and C. RX871024 stimulates increase in diacylglycerol levels in a fashion additive to that of the cholinergic agonist carbachol. A new generation of imidazolines with pure glucose-dependent insulinotropic activity includes BL11282. This potentiates glucose-induced insulin secretion without effect at low-glucose concentration, not acting on the K ATP channel, with effect seen both under depolarized and permeabilized conditions, in K ATP -deficient mice, and acting on protein kinases A and C. Zaitsev concluded that the new generation of imidazolines potentiate glucoseinduced insulin secretion and promote insulin exocytosis independently from blocking K ATP channel, directly stimulat- 
Metformin
David Moller (Rahway, NJ) discussed the molecular mechanism of action of metformin, pointing out that the medieval herbal treatment, French Lilac, was the original agent in this family. Metformin decreases gluconeogenesis (29) and has variable lipid-lowering effects, including actions on VLDL triglycerides and FFAs. There is evidence of a decrease in CVD mortality (30) and of protection against progression to diabetes (31).
Potential effects of metformin might involve the IR, the glucagon receptor, glucose transporters, and AMPK. There have also been studies suggesting that metformin decreases the activity of DPP-IV (32), and there is evidence that metformin potentiates the effect of infused GLP-1 (33), although no direct effect of metBloomgarden formin on DPP-IV has been demonstrated in vivo. Gastrointestinal absorption of glucose may be another potential site of action, although less well characterized.
Metformin decreases gluconeogenesis in hepatocytes, increases insulin action in myocytes (34) , and may inhibit mitochondrial oxidative phosphorylation (35) . All of these could involve AMPK, which is activated by AMP or adenosine nucleotides and has a variety of actions, including effects on fatty acid synthesis via acetyl CoA carboxylase (ACC) and on lipid synthesis, on muscle glucose uptake, and on nuclear transcription. In Moller's studies, both 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside (AICAR) and metformin activate AMPK, with the metformin effect occurring at levels seen with pharmacologic administration and appearing to operate via a different mechanism than that of AICAR (36) . The effect of metformin on AMPK appears to be indirect, as it is not seen in cell-free systems. In rodents, metformin decreases liver and muscle ACC activity (37) . Skeletal muscle biopsy studies in humans show increased AMPK activity with metformin treatment, and in rat hepatocyte studies, the effects of metformin can be reversed with an AMPK inhibitor, further suggesting this as an important mechanism. The inhibitory effects of metformin on ACC lead to increased oxidation and decreased synthesis of fatty acids, which may explain the decreases in circulating FFA and triglyceride levels seen with treatment, as well as antiobesity actions. Activation of AMPK by metformin suppresses the lipogenic transcription factor sterol regulatory elementbinding protein-1 (38) , perhaps contributing to the lipid-lowering effects and to the reported benefit of metformin in nonalcoholic fatty liver disease (39, 40) . Studies using a microarray system showing ϳ20,000 genes show considerable overlap of metformin with AICAR, including the downregulation of lipogenic factors, such as sterol regulatory elementbinding protein-1 and fatty acid synthase, and of gluconeogenic genes, including phosphoenolpyruvate carboxykinase and glucose-6 phosphatase. Muller concluded that AMPK appears to be an important drug target "to produce a better metformin," particularly as the effect of metformin on AMPK may be indirect, via its effect on oxidative phosphorylation, so that a direct activator of AMPK might lack the adverse potential to cause lactic acidosis. S. Del Guerra et al. ( 
